ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated)

ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Datasheet
  Order or Inquire for ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) product Quality antibodies Antibody production services
ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Product Information
Preparation :

ANXA5 / Annexin Ⅴ / Annexin A5 protein are conjugated with FITC under optimum conditions, the unreacted FITC was removed.

Concentration :

5 μl/Test, 0.1 mg/ml

Formulation : Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Applications : Flow Cytometry
Form & Shipping :

Liquid. Shipping at ambient temperature.

ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Usage Guide
Flow Cytometry :
ANXA5 / Annexin Ⅴ / Annexin A5 Flow Cytometry

Flow Cytometric Analysis of FITC Annexin V staining. Jurkat cells were untreated (top panels) or treated for 6 hours with 1 μM Camptothecin (Sigma,Cat.No C9911. bottom panels). Cells were incubated with FITC Annexin V in a buffer containing 7-Amino-Actinomycin (7-AAD,BD Pharmingen™ Cat. No.559925) and analyzed by flow cytometry. Untreated cells were primarily FITC Annexin V and 7-AAD negative, after a 6 hour treatment (bottom panels), there were primarily two populations of cells: Cells that were viable and not undergoing apoptosis (FITC Annexin V and 7-AAD negative); cells undergoing apoptosis (FITC Annexin V positive and 7-AAD negative). A minor population of cells were observed to be FITC Annexin V and 7-AAD positive, indicating that they were in end stage apoptosis or already dead.

Storage : This reagent is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Related Products & Topics

ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Related Areas:



ANXA5 / Annexin Ⅴ / Annexin A5 Protein (FITC conjugated) Background
Annexin Ⅴ, also known as Annexin A5 (ANXA5), they are abundant intracellular proteins, and several different annexin gene products are expressed in all mammalian cells examined to date. Antithrombotic effect exerted by Annexin A5 (ANXA5) is thought to be mediated mainly by forming a mechanical shield over phospholipids (PLs) reducing availability of PLs for coagulation reactions. However, more specific properties of ANXA5 might be of importance for its antithrombotic function. Such examples include downregulation of surface-expressed tissue factor (TF), as well as upregulation of urokinase-type plasminogen activator (uPA) by ANXA5. Also, interation of ANXA5 with ligands involved in hemostasis, such as sulfatide and heparin, has been demonstrated. Annexin V belongs to a family of Ca2+ binding proteins that undergo reversible Ca2+-dependent binding to phospholipids (PLs) that are located on the cytosolic face of the plasma membrane. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS to the external cellular environment, Annexin V has a high affinity for PS, and binds to cells with exposed PS. Annexin V may be conjugated to fluorochromes including FITC, PE. This format retains its high affinity for PS and thus serves as a sensitive probe for flow cytometric analysis of cells that are undergoing apoptosis.
  1. Cederholm A. et al., 2007, Ann N Y Acad Sci. 1108: 96-103.
  2. Schlaepfer DD. et al., 1992, Biochemistry. 311886-91.
  3. Vermes I. et al., 1995, J Immunol Methods. 184 (1): 39-51.

Annexin V/ANXA5 Background Information

The placental anticoagulant protein Annexin A5 (ANXA5) is a multifunctional protein that is highly expressed on the apical surfaces of syncytiotrophoblasts, and plays an important role in haemostatic regulations, maintaining blood fluidity of the placenta. Annexin A5 (ANXA5) is a protein abundantly expressed in normal placenta where it contributes to the healthy outcome of a pregnancy. Lower ANXA5 levels have been observed in M2/ANXA5 haplotype carrying chorion. The association found between the maternal carriage of the M2/ANXA5 haplotype and an elevated risk of IUGR and/or PE supports the hypothesis that carrier status of this haplotype and the consequently reduced placental ANXA5 expression might be responsible, at least partially, for the onset of these gestational vascular complications. ANXA5 could be used as a biomarker for the early detection of PE and for the prediction of its severity. ANXA5 as an embryonic anticoagulant that appears deficient in contiguous specter of thrombophilia-related pregnancy complications culminating more frequently in miscarriage in a maternal M2 carrier background. As a potential indicator for malignancy and lymphatic metastasis, ANXA5 overexpression increases in vitro migration and invasion of Hca-P cell, promotes in vivo malignancy, LNM rate and level of Hca-P-transplanted mice. Hereditary thrombophilias can impair vascular placental functions and predispose to the birth of small-for-gestational age (SGA) babies. The placental anticoagulant protein annexin A5 (ANXA5) may contribute to this process. A functional haplotype (M2) within the ANXA5 gene is associated with fetal loss and venous thrombosis.
Full Name
annexin A5
  • Cederholm A, et al. (2007) Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann N Y Acad Sci. 1108: 96-103.
  • Schlaepfer DD, et al. (1992) Inhibition of Protein Kinase C by AnnexinⅤ. Biochemistry. 31: 1886-91.
  • Vermes I, et al. (1995) A novel assay for apoptosis-flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin Ⅴ. J Immunol Methods. 184 (1): 39-51.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.